The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Santen’s Myopia Drug Approved in Europe
Santen Pharmaceutical said on June 5 that it has secured European regulatory approval for its low-dose atropine eye drop Ryjunea (atropine sulfate) for slowing the progression of pediatric myopia. The European Commission handed out its go-ahead for the drug to…
To read the full story
Related Article
- Santen’s Myopia Drug Ryjunea Now Available in Germany
July 23, 2025
- Santen’s Myopia Drug Recommended for European Approval
April 1, 2025
BUSINESS
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
- Rohto to Roll Out 3- or 4-Day Workweek Option from April to Spur Growth, Retention
January 15, 2026
- Rakuten Joins Hands with LOTTE Biologics to Boost Production for Photoimmunotherapy
January 15, 2026
- Daiichi Sankyo Unveils Brand Site for OTC NorLevo Ahead of Launch
January 15, 2026
- Cheplapharm to Take Over Japan MA for UCB’s Myocalm
January 15, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…